Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prenylated xanthones as potential P-glycoprotein modulators.

D N Tchamo1, M G Dijoux-Franca, A M Mariotte

  • 1Laboratoire de Pharmacognosie, DPM (UMR 5063 CNRS-UJF), Université Grenoble I, Faculté de Pharmacie, La Tronche, France.

Bioorganic & Medicinal Chemistry Letters
|July 13, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma.

ESMO real world data and digital oncology·2026
Same author

Measurement of ^{19}F(p, αγ)^{16}O Reaction Reopens the Fluorine Conundrums in Stars.

Physical review letters·2025
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

ESMO open·2025
Same author

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

ESMO open·2023
Same author

Antibacterial activity of nanoparticles and nanomaterials: a possible weapon in the fight against healthcare-associated infections.

European review for medical and pharmacological sciences·2023

Dimethylallyl derivatives of decussatin 1 were synthesized and tested as P-glycoprotein inhibitors. Reduced polarity and specific hydroxyl groups enhanced binding affinity, showing similar structure-activity relationships to DMA-flavones.

Area of Science:

  • Natural Product Chemistry
  • Medicinal Chemistry
  • Biochemistry

Background:

  • P-glycoprotein (P-gp) is a key efflux pump involved in multidrug resistance.
  • Xanthones and flavones are natural product classes with diverse biological activities.
  • Modulating P-gp activity is a strategy to overcome drug resistance.

Purpose of the Study:

  • To synthesize dimethylallyl (DMA) derivatives of the natural xanthone decussatin 1.
  • To evaluate their potential as P-glycoprotein (P-gp) inhibitors.
  • To compare their structure-activity relationships with corresponding DMA-flavones.

Main Methods:

  • Synthesis of DMA derivatives of decussatin 1.
  • Affinity-based direct binding assays to assess P-gp inhibition.

Related Experiment Videos

  • Comparative analysis of binding affinities and structure-activity relationships.

    • Main Results:

    • Both DMA-xanthone and DMA-flavone derivatives demonstrated P-gp inhibitory activity.
    • Decreased compound polarity correlated with enhanced binding affinity to the P-gp C-terminal cytosolic domain.
    • An unsubstituted hydroxyl group adjacent to the carbonyl moiety was crucial for potent activity.

    Conclusions:

    • DMA derivatives of decussatin 1 are potential P-gp inhibitors.
    • Structural modifications, specifically reduced polarity and hydroxyl group positioning, can optimize P-gp inhibitory activity.
    • These findings provide insights into the design of novel P-gp modulators based on natural product scaffolds.